Mammalian Cell Fermentation Technology Market To Reach $76.24 Billion By 2030

Mammalian Cell Fermentation Technology Market Growth & Trends 

The global mammalian cell fermentation technology market size is expected to reach USD 76.24 billion by 2030, registering at a CAGR of 8.64%, according to a new report by Grand View Research, Inc. A crucial step in the creation and manufacture of biologics is the utilization of mammalian cell fermentation technology. Several biologics are made with this fermentation technology which is used to treat a variety of illnesses including cancer, autoimmune disorders, and infectious diseases. Mammalian cells, primarily Chinese Hamster Ovary (CHO) cells, are employed in the technique to make proteins that are then purified and combined to create biologic pharmaceuticals. These cells are cultured in large-scale bioreactors. The need for biologics and biosimilars has increased the significance of technology in the biopharmaceutical sector. 

The mammalian cell fermentation technology industry is expected to see significant growth in the coming years due to various factors, including the increasing demand for biologics and biosimilars, advancements in mammalian cell culture techniques, and the growing prevalence of chronic diseases. For instance, in January 2021, Merck KGaA acquired AmpTec, a German-based biotech company. This acquisition will enable Merck to expand its capabilities in mRNA technology, a field that is rapidly growing in importance for the development of biologics, biosimilar and mammalian cells. Additionally, the acquisition will strengthen Merck's position in the fast-growing mRNA contract development and manufacturing organization (CDMO) market. 

The COVID-19 pandemic has also emphasized the value of biology and the necessity for efficient medicines, which has aided in the expansion of the marketplace for mammalian cell fermentation technology industry. For instance, the COVID-19 vaccine was created by the biotech company Moderna using mammalian cell fermentation technology, and it has been approved for use in emergencies worldwide. This example highlights how mammalian cell fermentation technology has played a critical role in the development of life-saving treatments and therapies during the pandemic and its potential for future growth.

 Request a free sample copy or view report summary: Mammalian Cell Fermentation Technology Market Report

Mammalian Cell Fermentation Technology Market Report Highlights

• By type, Chinese Hamster Ovary (CHO) cell fermentation segment dominated the market in 2022 with a share of 65.52%, due to its well-understood genetic and biochemical characteristics, high productivity, affordability, and regulatory acceptability, which have been optimized and researched over time

• By application, monoclonal antibodies had a dominant presence in the market with a share of 42.38% in the year 2022, due to their effectiveness in treating various diseases, including COVID-19

• By end-use, CMOs & CDMOs segment held the largest market share of 51.00% in 2022, due to the increasing trend of outsourcing biopharmaceutical production to third-party manufacturers. CDMOs offer specialized expertise, infrastructure, and equipment necessary for efficient production, which makes them a popular choice among biopharmaceutical companies

• North America established a strong regional position in the market with a 37.61% share in 2022. Due to its highly developed healthcare infrastructure, favorable government policies, and a strong presence of major biopharmaceutical companies

Mammalian Cell Fermentation Technology Market Segmentation

Grand View Research has segmented the global mammalian cell fermentation technology market based on type, application, end-use, and region: 

Mammalian Cell Fermentation Technology Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Chinese Hamster Ovary (CHO) Cell Fermentation

• Human Embryonic Kidney (HEK) Cell Fermentation

• Baby Hamster Kidney (BHK) Cell Fermentation

• Murine Myeloma Cell Fermentation

• Others

Mammalian Cell Fermentation Technology Application Outlook (Revenue, USD Billion, 2018 - 2030)

• Monoclonal Antibodies

• Recombinant Proteins

• Vaccines

• Hormones

• Enzymes

• Others

Mammalian Cell Fermentation Technology End-Use Outlook (Revenue, USD Billion, 2018 - 2030)

• Biopharmaceutical Companies

• CMOs & CDMOs

• Academic & Research Institutes

Mammalian Cell Fermentation Technology Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Mammalian Cell Fermentation Technology Market

• Thermo Fisher Scientific, Inc.

• Merck KGaA

• Danaher

• Lonza

• F. Hoffmann-La Roche Ltd

• Sartorius AG

• AstraZeneca

• Bristol-Myers Squibb

• Amgen

• Gilead Sciences

• Moderna, Inc.

• Regeneron Pharmaceuticals